Orthofix goes for experience with new chair Matricaria
This article was originally published in Clinica
Troubled Orthofix International will be hoping medical device veteran Ronald Matricaria, who it has just appointed director and chair, will be able to help dig it out of its current hole. The company is fighting delisting from the Nasdaq after delaying reporting its quarterly results, and also had a torrid 2013, with weak sales and questions over its business practices. In March 2013, it appointed Brad Mason CEO after previous incumbent Bob Vaters stepped down suddenly. New chair Mr Matricaria has over 35 years of experience at St Jude Medical and pharma giant Eli Lilly. He is also currently chair of Volcano and, most recently, served as a director at Life Technologies (acquired by Thermo Fisher for $13.6bn). He replaces Kathleen Regan, who has served as interim chair since January.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.